A combination of BRAF (dabrafenib) and MEK (trametinib) inhibitors is used for the treatment of metastatic melanoma with BRAFV600E mutation and these inhibitors observed an increase in KIT expression (tumor suppressor gene) and induced alterations in CCND1, RB1, and MET in patients with metastatic melanoma [66]. This evidence concerns the gene BRAF and metastatic melanoma.